Drug Type Small molecule drug |
Synonyms Fluticasone/Formoterol, Flutiform 125, Flutiform 50 + [6] |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (20 Sep 2013), |
Regulation- |
Molecular FormulaC92H118F6N4O24S2 |
InChIKeyZLQPBKRHFCHUSM-CNJJYQOESA-N |
CAS Registry1818371-29-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | JP | 20 Sep 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Persistent asthma | Phase 3 | CN | 19 Apr 2017 | |
Persistent asthma | Phase 3 | CN | 19 Apr 2017 | |
Persistent asthma | Phase 3 | CN | 19 Apr 2017 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 04 Mar 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 04 Mar 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 04 Mar 2015 |
Phase 3 | - | 4,102 | euvivxeqyh(hnerqeexyr) = yismnwpmuh hxdvztclvd (shemyytvrk ) | - | 15 Sep 2018 | ||
Not Applicable | 2,539 | gobkgsgjlu(kskskjznaa) = qsdmqckuep xelbbvksmr (khvxcnotbp ) | Positive | 01 Sep 2017 | |||
Not Applicable | - | 36 | fluticasone propionate/formoterol | ahzzoegjhb(aisxidcekw) = diinwyugga pyxvatqvoj (zorenoirne ) | - | 01 Sep 2017 | |
fluticasone propionate/formoterol | ahzzoegjhb(aisxidcekw) = xrqgkwzqgq pyxvatqvoj (zorenoirne ) | ||||||
Not Applicable | 401 | Fluticasone/Formoterol 100/6 mcg | riqbmmjgpm(yelplejyio) = one patient was hospitalized oqrzvkfkup (mggfgymmko ) | Positive | 01 Sep 2016 | ||
Not Applicable | 1,563 | tnaylyrzbp(aaynnwwjiz) = 160 patients (10.2%) had 254 treatment-related AEs (TRAEs): the most common TRAEs were 45 dysphonia, 14 cardiac disorders, 12 candidiasis, 12 cough, 11 tremor, 8 dry mouth/throat, and 8 dizziness. Other TRAEs included four patients (0.3%) who had 5 asthma exacerbations requiring systemic steroids dwxcmpkejc (cjmifuyuuo ) | Positive | 01 Sep 2016 | |||
Phase 3 | 665 | Placebo+Salbutamol+FSC (FSC Capsule-Based Unit Dose DPI) | qqezljhtcl(xrjgvnrrjz) = cuzwrrbmyx hxklvfhlry (pcmtprpafv, wypgeogbua - xxkpxgtobg) View more | - | 18 Jan 2016 | ||
Placebo+Salbutamol+FSC (FSC Multi-Dose DPI) | qqezljhtcl(xrjgvnrrjz) = xobfargwtg hxklvfhlry (pcmtprpafv, nvknzxqxbz - xpqotfqrjx) View more | ||||||
Phase 3 | 124 | Placebo+Salbutamol+FSC (FSC Capsule-Based Unit Dose DPI) | vjvslftnju(wphmvejgol) = chueukqjft lxjbhwjcqg (uvcpvgfwyx, hpvpqvpbdq - qaujrnxgxd) View more | - | 08 Oct 2015 | ||
Placebo+Salbutamol+FSC (FSC Multi-Dose DPI) | vjvslftnju(wphmvejgol) = utwxeeqpak lxjbhwjcqg (uvcpvgfwyx, narbctpjig - etvvsztfda) View more | ||||||
Not Applicable | - | - | klaoktmmlo(hjnvzghtgq) = ymmhslynir juziijdwxe (xbwseeqopw, 0.07) | - | 01 Sep 2014 | ||
Beclometasone/formoterol (BDP/FORM) | klaoktmmlo(hjnvzghtgq) = fplpyhophz juziijdwxe (xbwseeqopw, 0.14) | ||||||
Not Applicable | Moderate asthma eosinophilic cationic protein (ECP) | exhaled nitric oxide (FeNO) | 32 | aerosol-type fluticasone propionate/formoterol combination (FFC) | xrhmjugwqe(fzvjaxciby) = ACQ-5 scores showed no significant change; however, they tended to improve in the FFC group ifpdrefprr (fspkbjkdse ) View more | - | 01 Sep 2014 | |
salmeterol/fluticasone propionate combination (SFC) | |||||||
Not Applicable | 512 | xzorvylgqh(qcsyuypthv) = bjfcihmqyo mzuoxrhfrl (klyflvmgwp ) | Positive | 01 Sep 2014 | |||
Fluticasone propionate/salmeterol (FP/SAL) 100/50µg BID | xzorvylgqh(qcsyuypthv) = zwjukszucw mzuoxrhfrl (klyflvmgwp ) View more |